In the study by Tong et al. [68], the authors did not find any correlation between MCT1 expression and OS, but MCT4 expression was reported to be an independent predictive marker for worse overall prognosis of NSCLC patients; interestingly, these authors stated that patients with MCT1-positive and MCT4-negative tumours (concurrently) are most likely to respond to AZD3965 therapy, as discussed elsewhere [37]. The gene discussed is SLC16A1; the disease is neoplasm.